FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with 160+ patents, announced upcoming presentations at two major conferences. The company will present at the 2024 ThinkEquity Conference in New York on October 30, 2024, at 10:30 a.m. ET, and at BIO-Europe 2024 in Stockholm on November 5, 2024, at 1:30 p.m. CET.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. Their patent portfolio covers various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
FibroBiologics (Nasdaq: FBLG), una compagnia biotecnologica in fase clinica con oltre 160 brevetti, ha annunciato prossime presentazioni a due importanti conferenze. L'azienda presenterà alla 2024 ThinkEquity Conference a New York il 30 ottobre 2024, alle 10:30 ET, e alla BIO-Europe 2024 a Stoccolma il 5 novembre 2024, alle 13:30 CET.
FibroBiologics si specializza nello sviluppo di terapie e potenziali cure per malattie croniche utilizzando fibroblasti e materiali derivati dai fibroblasti. Il loro portafoglio di brevetti copre vari percorsi clinici, tra cui degenerazione del disco, ortopedia, sclerosi multipla, psoriasi, guarigione delle ferite, inversione dell'involuzione degli organi e cancro.
FibroBiologics (Nasdaq: FBLG), una empresa de biotecnología en etapa clínica con más de 160 patentes, anunció próximas presentaciones en dos importantes conferencias. La compañía presentará en la 2024 ThinkEquity Conference en Nueva York el 30 de octubre de 2024, a las 10:30 a.m. ET, y en la BIO-Europe 2024 en Estocolmo el 5 de noviembre de 2024, a la 1:30 p.m. CET.
FibroBiologics se especializa en el desarrollo de terapias y posibles curas para enfermedades crónicas utilizando fibroblastos y materiales derivados de fibroblastos. Su cartera de patentes abarca diversas vías clínicas, que incluyen la degeneración del disco, ortopedia, esclerosis múltiple, psoriasis, curación de heridas, inversión de la involución de órganos y cáncer.
FibroBiologics (Nasdaq: FBLG)는 160개 이상의 특허를 보유한 임상 단계의 생명공학 회사로, 두 개의 주요 회의에서 발표할 예정이라고 발표했습니다. 이 회사는 2024년 10월 30일 오전 10시 30분 ET에 뉴욕에서 2024 ThinkEquity Conference에서 발표하고, 2024년 11월 5일 오후 1시 30분 CET에 스톡홀름에서 BIO-Europe 2024에서 발표할 것입니다.
FibroBiologics는 섬유모세포 및 섬유모세포 유래 물질을 사용하여 만성 질환에 대한 치료법과 잠재적인 치료제를 개발하는 데 전문화되어 있습니다. 그들의 특허 포트폴리오는 디스크 퇴화, 정형외과, 다발성 경화증, 건선, 상처 치유, 장기 퇴화 역전 및 암을 포함한 다양한 임상 경로를 다룹니다.
FibroBiologics (Nasdaq: FBLG), une entreprise de biotechnologie en phase clinique avec plus de 160 brevets, a annoncé de prochaines présentations lors de deux grandes conférences. La société présentera à la 2024 ThinkEquity Conference à New York le 30 octobre 2024, à 10h30 ET, et à la BIO-Europe 2024 à Stockholm le 5 novembre 2024, à 13h30 CET.
FibroBiologics se spécialise dans le développement de thérapies et de traitements potentiels pour les maladies chroniques en utilisant des fibroblastes et des matériaux dérivés de fibroblastes. Leur portefeuille de brevets couvre divers parcours cliniques, y compris la dégénérescence du disque, l'orthopédie, la sclérose en plaques, le psoriasis, la cicatrisation des plaies, l'inversion de l'involution des organes et le cancer.
FibroBiologics (Nasdaq: FBLG), ein biopharmazeutisches Unternehmen in der klinischen Phase mit über 160 Patenten, gab die bevorstehenden Präsentationen auf zwei großen Konferenzen bekannt. Das Unternehmen wird am 30. Oktober 2024 um 10:30 Uhr ET auf der 2024 ThinkEquity Conference in New York und am 5. November 2024 um 13:30 Uhr CET auf der BIO-Europe 2024 in Stockholm präsentieren.
FibroBiologics spezialisiert sich auf die Entwicklung von Therapeutika und potenziellen Heilmitteln für chronische Erkrankungen unter Verwendung von Fibroblasten und fibrogenen Materialien. Ihr Patentportfolio deckt verschiedene klinische Wege ab, darunter Bandscheibendegeneration, Orthopädie, Multiples Sklerose, Psoriasis, Wundheilung, Umkehrung der Organinvolution und Krebs.
- None.
- None.
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences.
2024 ThinkEquity Conference
Date: October 30, 2024
Location: New York, NY
Format: Company Presentation
Time: 10:30 a.m. ET
BIO-Europe 2024
Date: November 5, 2024
Location: Stockholm, Sweden
Format: Company Presentation
Time: 1:30 p.m. CET
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When is FibroBiologics (FBLG) presenting at the 2024 ThinkEquity Conference?
What time is FibroBiologics (FBLG) presenting at BIO-Europe 2024?
How many patents does FibroBiologics (FBLG) currently hold?
What medical conditions does FibroBiologics (FBLG) focus on treating?
